Smoking hot minis
PARSIPPANY, N.J. —GlaxoSmithKline in April announced the launch of its new Nicorette Mini Lozenge, a smaller smoking cessation lozenge that dissolves three times faster than stop-smoking lozenges currently on the market. The lozenges will be line-priced with existing smoking cessation products and will be sold as three small vials each containing 27 lozenges.
The new mini-lozenge is expected to drive incremental growth to the category, suggested Roger Scarlett-Smith, GSK president of consumer healthcare, North America, because the smaller lozenge size actually satisfies different usage scenarios. “It’s an opportunity for people to use it in a more situational way,” Scarlett-Smith said. That may mean a resurgence in sales of smoking cessation products, which were relatively fl at (down slightly by 0.9%) for the 52 weeks ended April 18 with sales of $513 million across food, drug and mass (excluding Walmart), according to SymphonyIRI Group data.
The small vials can be discreetly carried in a pocket for the person “on the go,” Scarlett-Smith said. And because there are three vials per package, they can be strategically placed in trouble areas for the person attempting to quit smoking.
Congressional committee investigates J&J’s Motrin ‘phantom’ recall
WASHINGTON Rep. Ed Towns, D-N.Y., on Thursday announced that the Committee on Government Oversight and Government Reform, which he chairs, has begun querying contracting companies on whether they were hired by Johnson & Johnson in late 2008 to execute a “phantom” recall of a certain SKU of Motrin available primarily through the convenience channel.
“Rather than doing the right thing and announcing a recall, we have learned that the drug company hired contractors to basically sneak into stores to purchase the products as if they were legitimate customers,” stated Towns. “We need to better understand Johnson & Johnson’s relationship with the contractor and get to the bottom of the services the contractor was asked to provide.”
Towns had addressed the Motrin recall with Colleen Goggins, J&J worldwide chairman, consumer group, during last week’s hearing. Goggins testified that she did not know the specific language of the contract between J&J and the contractor, but that the Food and Drug Administration had knowledge of J&J’s particular actions in this situation at the time the contract was being executed.
The committee is examining an alleged attempt by J&J, parent company of McNeil Consumer Healthcare, to hire a contractor to go into retail stores and secretly purchase the suspect Motrin in order to avoid issuing a formal recall. Only when the FDA discovered this covert activity did J&J announce a recall of the affected medication, Towns asserted. “It wasn’t until this caper was foiled by the Food and Drug Administration that McNeil did what it should have done in the first place and recalled the affected medication,” Towns said. “The company’s motivation was apparently to save itself the embarrassment and potential financial loss associated with a recall.”
According to a document obtained by the Committee, WIS of San Diego was recruited by Carolina Supply Chain Services, now a division of Inmar, “on behalf of Johnson & Johnson” to purchase the affected Motrin.
Chairman Towns sent formal requests for information to WIS and Inmar today about their relationship with J&J, and asked for details on their alleged role in the phantom recall. The chairman also asked for the amount of Motrin that was purchased and what was done with those packages.
The committee learned of the phantom recall while investigating the recent recall of over-the-counter Johnson & Johnson/McNeil pediatric products, Towns said. This week, the chairman expanded that investigation to include the issue of Johnson & Johnson’s phantom recall of Motrin.
Perrigo receives FDA approval for generic Monistat-1 Combination Pack
ALLEGAN, Mich. Perrigo on Thursday announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for over-the-counter miconazole nitrate vaginal cream and suppository, a generic to Monistat-1 Combination Pack, and expects to begin shipping immediately.
Annual sales of Monistat-1 totaled approximately $90 million and is indicated for the treatment of vaginal yeast infections and for the relief of external itching and irritation they cause, Perrigo reported.
Perrigo was the first to file an ANDA containing a Paragraph IV certification, and the resulting patent litigation filed by Johnson & Johnson previously was dismissed. Perrigo’s approval included 180 days of generic marketing exclusivity.